Ischemix is a privately-held pharmaceutical company that has developed novel cytoprotective compounds for the prevention and treatment of serious conditions of the kidney, heart, and other organ systems. Founded in 1999 in the United States, the company received a significant $6.60M Venture Round investment on June 5, 2014. Ischemix's focus on developing innovative solutions for critical medical needs positions it as an intriguing prospect for venture capital investors seeking opportunities in the pharmaceutical and biotech industries. With its cutting-edge approach to cytoprotection, Ischemix has the potential to make a meaningful impact on the treatment and prevention of severe organ system conditions, making it an attractive option for investors looking to tap into the healthcare innovation space.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $6.60M | - | 05 Jun 2014 |
No recent news or press coverage available for Ischemix.
We care about your data, and we'd love to use cookies make your experience better.
